Business Wire

  1. Charles River Laboratories And Atomwise Form A Strategic Alliance To Provide Integrated, Artificial Intelligence-Driven Drug Discovery
    1/11/2019

    Charles River Laboratories International, Inc. and Atomwise, Inc. recently announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, structure-based, drug design technology, which allows scientists to predict how well a small molecule will bind to a target protein of interest

  2. Ocular Therapeutix Submits Supplemental New Drug Application (sNDA) For DEXTENZA (Dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery
    1/10/2019

    Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA (dexamethasone ophthalmic insert)

  3. Elevian And Insilico Enter A Research Collaboration To Discover Drugs That Target Aging
    1/9/2019

    On the final day of the largest biotechnology and pharmaceutical partnering week at the Juvenescence Longevity Showcase two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets

  4. Numerate And Lundbeck Partner To Apply AI Drug Discovery To Unlock Challenges Of Neuroscience Research
    1/7/2019

    Numerate, Inc., a data-driven drug design company applying artificial intelligence (AI) to transform drug discovery, announced a multi-target research collaboration with Lundbeck Pharmaceutical to identify clinical candidates for the treatment of disorders in the central nervous system, including depression, psychosis, seizure and neurodegenerative disorders

  5. CytoReason Signs Collaboration Agreement With Pfizer Inc. To Utilize CytoReason’s Machine Learning Model Of The Immune System For Drug Discovery
    1/7/2019

    CytoReason, a leader in machine learning for drug discovery and development, announced recently that it has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE) that will leverage CytoReason’s cell-centered models of the immune system

  6. Horizon Pharma plc And HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration In Gout
    1/3/2019

    Horizon Pharma plc and HemoShear Therapeutics, LLC, a privately held biotechnology company, recently announced a collaboration to discover and develop novel therapeutics for gout

  7. Ablexis Announces Licensing Agreement With Corvidia Therapeutics
    1/3/2019

    Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, recently announced a license agreement with Corvidia Therapeutics Inc

  8. Lupin And AbbVie Announce Partnership To Develop And Commercialize Novel Oncology Drug To Treat Hematological Cancers
    12/24/2018

    Pharma major Lupin Limited (Lupin) and global biopharmaceutical company AbbVie Inc., recently announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program

  9. Ayala Pharmaceuticals Signs Deal To Develop And Commercialize AL102 In Combination With BCMA Targeting Agents In Multiple Myeloma
    12/20/2018

    Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically identified, announced recently that it entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma

  10. Spirita Oncology Initiated Global Clinical Development Of E6201 In Collaboration With JS InnoPharm (Shanghai) Under Strategic Partnership Alliance And Sub-License Agreement
    12/19/2018

    Spirita Oncology, LLC, announced that it has entered into a sublicense agreement with JS Innopharm (Shanghai) Ltd. to initiate global clinical development of E6201, a potent MEK1 inhibitor with excellent brain penetration. In August 2018, Strategia Holdings, LLC, a parent company of Spirita Oncology, LLC, and JS Innopharm initiated a Strategic Partnership Alliance to facilitate global drug development